Hypoglycemia (when combined) on Mounjaro (tirzepatide for T2D): Week-by-Week Timeline of What to Expect

What the Mounjaro label says about combining it with insulin or a sulfonylurea

Section 5.3 of the Mounjaro prescribing information states that patients receiving Mounjaro in combination with an insulin secretagogue (for example a sulfonylurea) or with insulin may have an increased risk of hypoglycemia, including severe hypoglycemia, and that the risk may be lowered by a reduction in the dose of the sulfonylurea or insulin [1]. The same section tells prescribers to inform patients using those medicines of the risk and to educate them on the signs and symptoms of hypoglycemia [1].

The drug interactions section (7.1) says that when initiating Mounjaro, consider reducing the dose of the concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia [1]. Neither section gives an amount for the reduction [1].

A 2024 review of GLP-1-based therapies, including tirzepatide, notes that these drugs slow gastric emptying, which lowers postprandial glucose but also carries a potential risk of hypoglycemia in people on insulin or sulfonylurea therapy [2].

What the dose schedule means for timing

The Mounjaro label specifies a starting dose of 2.5 mg injected once weekly and permits increases of 2.5 mg after at least 4 weeks on the current dose if additional glycemic control is needed, to a maximum of 15 mg weekly in adults and 10 mg weekly in patients 10 years and older [1]. The label ties that stepwise schedule to reducing the risk of gastrointestinal adverse reactions [1]. Its advice about the sulfonylurea or insulin is worded for the time Mounjaro is initiated [1].

What the trials show over time

The label's two placebo-controlled adult trials each ran 40 weeks [1]. In SURPASS-5, Mounjaro added to basal insulin with or without metformin, glucose under 54 mg/dL occurred in 16%, 19% and 14% of patients on 5 mg, 10 mg and 15 mg, versus 13% on placebo. Severe hypoglycemia was reported in none of the placebo or 5 mg patients, 2% on 10 mg and 1% on 15 mg [1]. In SURPASS-1, a monotherapy trial, glucose under 54 mg/dL occurred in 0% of patients on each Mounjaro dose and 1% on placebo, with no severe hypoglycemia [1].

A 104-week post hoc analysis of SURPASS-4 included 1,500 participants with type 2 diabetes inadequately controlled on metformin and/or a sulfonylurea; the incidence of hypoglycemia was lower in the tirzepatide groups than in the insulin glargine group [3]. That comparison is against insulin glargine, not against staying on a sulfonylurea alone.